Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.

Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.

T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.

The rate of local recurrence was lower in patients who received chest wall irradiation, but this was considered clinically insignificant. Chest wall irradiation after mastectomy does not improve ...

Modified Radiation-Induced Skin Reaction Assessment Scale scores were lower with Mepitel Film than with standard care. The use of Mepitel Film, a silicone-based dressing applied to skin, can reduce ...

Omitting axillary SLNB does not impact outcomes in patients with early invasive breast cancer undergoing breast-conserving surgery, data suggest.

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

The 36-month overall survival rate was 74% in the belantamab mafodotin arm and 60% in the daratumumab arm. Belantamab ...

Imlunestrant, given alone or in combination with abemaciclib, has demonstrated efficacy in patients with ER+, HER2- advanced breast cancer.

Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.